XPro1595
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
2
Sites
49
Countries
8
Endpoints
52
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 52 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 11 of 52 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
5
4
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| MINDFuLA Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | XPro1595 Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 41 | May 2025 | 4 | results |
| NCT03943264A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's | XPro1595 Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 5 | Jun 2021 | 4 | |
| NCT05522387An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | XPro1595 Alzheimer’s disease | Study partner/caregiver required | Ph 2 | Terminated | 4 | Jun 2024 | 42 | |
| NCT05321498Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation | XPro1595 Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Withdrawn | 0 | Oct 2023 | 4 |
Showing 1-4 of 4 trials